DATA GRAPHICS | Data Byte
Ozempic continues dominance in GLP-1 race
Mounjaro 4Q22 sales fall short of expectations after strong first quarter
February 2, 2023 7:44 PM UTC
Ozempic is maintaining its leadership position in an expanding GLP-1 market, while new entrant Mounjaro disappointed high expectations for its second full quarter on the market.
On Wednesday, Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said 2022 sales of once-weekly GLP-1 agonist Ozempic semaglutide were DKK59.8 billion ($8.6 billion), an increase of 77% vs. 2021. For the fourth quarter, Ozempic posted DKK16.98 billion, short of the Street estimate of DKK17.74 billion...